Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2020 Earnings Results

Alnylam Pharmaceuticals Misses on Revenue, Stock Down 4.20%

This earnings report indicates that Alnylam Pharmaceuticals is facing challenges, particularly in revenue generation. The stock reacted negatively, dropping 4.20%, likely due to the lack of revenue data and cautious management tone. Investors may be concerned about the company's ability to navigate current market conditions effectively.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-1.67	N/A	+8.39%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed concerns about market conditions affecting performance. They remain focused on strategic initiatives to drive future growth.

Management highlighted ongoing challenges in the current market environment.

They emphasized a commitment to long-term growth despite short-term setbacks.

Alnylam Pharmaceuticals Misses on Revenue, Stock Down 4.20%

Key numbers

Management commentary

Alnylam Pharmaceuticals, Inc.

More earnings this week

Alnylam Pharmaceuticals Misses on Revenue, Stock Down 4.20%

Key numbers

Management commentary